Stay updated on Response-guided Neoadj HER2+ Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Response-guided Neoadj HER2+ Breast Cancer Clinical Trial page.

Latest updates to the Response-guided Neoadj HER2+ Breast Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedNew revision entry added to the Record History: Revision: v3.3.2 is listed, replacing v3.3.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check27 days agoChange DetectedNew revision v3.3.1 was added to the study record history while v3.2.0 was removed, with updates spanning study status, arms/interventions, and outcome measures. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check35 days agoChange DetectedRemoved a government funding and operating status notice from the page, deleting a banner about potential data delays and links to cc.nih.gov and opm.gov.SummaryDifference0.8%

- Check49 days agoChange DetectedThe history shows updates to Study Status and Recruitment Status across versions (e.g., 2015-10-27 Study Status; 2019-02-10 Recruitment Status; 2020-08-11 Study Status Arms and Interventions), reflecting changes in the trial's activity and enrollment over time.SummaryDifference0.1%

- Check78 days agoChange DetectedKey updates: version bump to v3.2.0 and an important government-operating-status notice; the previous v3.1.0 reference was removed. Overall, user-facing status and versioning information were updated. If no other content changed, this is a targeted update to status and versioning.SummaryDifference13%

- Check85 days agoChange DetectedUpdate: revision tag changed from v3.0.2 to v3.1.0; no substantive content changes detected.SummaryDifference0.3%

Stay in the know with updates to Response-guided Neoadj HER2+ Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Response-guided Neoadj HER2+ Breast Cancer Clinical Trial page.